Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H45NO |
| Molecular Weight | 399.6523 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(CC[C@@]2([H])[C@]3([H])CCC4=C\C(CC[C@]4(C)[C@@]3([H])CC[C@]12C)=N\O)[C@H](C)CCCC(C)C
InChI
InChIKey=QNTASHOAVRSLMD-SIWSWZRQSA-N
InChI=1S/C27H45NO/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28-29)13-15-26(20,4)25(22)14-16-27(23,24)5/h17-19,22-25,29H,6-16H2,1-5H3/b28-21+/t19-,22+,23-,24+,25+,26+,27-/m1/s1
| Molecular Formula | C27H45NO |
| Molecular Weight | 399.6523 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Olesoxime (TRO19622) a small-molecule with a cholesterol-like structure has remarkable neuroprotective properties for motor neurons in cell culture and in rodents. The biopharmaceutical company Trophos initially developed this compound. This medicine is in phase II clinical trial in treating spinal muscular atrophy and in phase I for patients with stable relapsing remitting multiple sclerosis. This drug was also investigated in phase III clinical trial for amyotrophic lateral sclerosis, but it did not demonstrate a significant increase in survival versus placebo and that study was discontinued. Preclinical studies have demonstrated that the olesoxime promoted the function and survival of neurons and other cell types under disease-relevant stress conditions through interactions with the mitochondrial permeability transition pore (mPTP).
Originator
Approval Year
Sample Use Guides
Participants will receive 10 milligrams per kilogram (mg/kg) suspension once a day either orally or via a naso-gastric or gastrostomy tube with the main meal (preferably at the same time of the day)
Route of Administration:
Oral
Neuroprotective dose-effect of olesoxime against motor neuron cell death was studied. Rat embryonic motor neurons were cultured in 96-well plates in the absence of trophic factors and with increasing concentrations of olesoxime (concentrations ranging from 0.1 to 10 µM), or with pure syn or anti forms of olesoxime. Motor neuron survival was measured after 3 days or 7 days in vitro by direct counting of live cells labeled with calcein-AM. Survival is expressed as a ratio of surviving cell (A-B) relative to positive controls treated with a cocktail of neurotrophic factors (NTFs) and negative controls that received DMSO alone (0.1%). Treatment with olesoxime produced a dose-dependent increase in cell survival with EC50 around 3 µM. Importantly, both syn and anti forms were equally potent.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:50:01 GMT 2023
by
admin
on
Sat Dec 16 08:50:01 GMT 2023
|
| Record UNII |
8V8EF6094N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9930827
Created by
admin on Sat Dec 16 08:50:01 GMT 2023 , Edited by admin on Sat Dec 16 08:50:01 GMT 2023
|
PRIMARY | |||
|
66538-08-7
Created by
admin on Sat Dec 16 08:50:01 GMT 2023 , Edited by admin on Sat Dec 16 08:50:01 GMT 2023
|
PRIMARY | |||
|
8V8EF6094N
Created by
admin on Sat Dec 16 08:50:01 GMT 2023 , Edited by admin on Sat Dec 16 08:50:01 GMT 2023
|
PRIMARY |